Full-Time
Senior Counsel
Weiss Asset Management
51-200 employees
Value-based investment firm managing $2.7B
Compensation Overview
$220k - $270k/yr
Boston, MA, USA
In Person
 Legal & Compliance (1) |
|---|
Get referred to Weiss Asset Management
See people who can refer or advise you
- At least 4 years of experience in some or all of the following areas: regulatory advice, negotiation of transactions and agreements, investment-related legal advice, and general corporate work.
- Strong academic credentials.
- High ethical standards, attention to detail, strong interpersonal skills, quantitative reasoning ability, and a rigorous work ethic.
- Provide regulatory advice.
- Negotiate transactions and agreements.
- Provide investment-related legal advice.
- Perform general corporate legal work.
- Engage in multiple substantive legal areas and address diverse business challenges of a global hedge fund.
- Experience at a large law firm and/or an asset management firm.
Weiss Asset Management manages about $2.7 billion across hedge funds and institutional accounts, using proprietary, value-based investment strategies to deliver high risk-adjusted returns for clients such as foundations, pension plans, endowments, hospitals, and government entities. The firm combines deep fundamental research, statistical analysis, and rigorous decision-making to identify undervalued assets. It differentiates itself through a collaborative problem-solving culture, a long 30-year track record, and a disciplined, rational approach guided by integrity, creativity, and continuous learning. The goal is to grow and protect client wealth by applying disciplined value investing and ongoing improvement in methods.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Boston, Massachusetts
Founded
1991
Get referred to Weiss Asset Management
See people who can refer or advise you
Simplify's Take
What believers are saying
- June 2026 OliX raised KRW 110 billion with Weiss beside L'Oréal's BOLD fund.
- March 2026 ROKIT and Neotis deals show continued access to Korean growth financings.
- July 2026 buys in Wabtec, Booz Allen, and News Corp signal active public-market deployment.
What critics are saying
- Public filings reveal strategy, not the people; hiring depends on founder-driven key-person risk.
- June 2026 OliX and March 2026 ROKIT tie capital to binary biotech outcomes and lockups.
- A bad 13F cycle or one flagship loss can erase sourcing credibility by 2027.
What makes Weiss Asset Management unique
- Weiss pairs fundamental research with statistical analysis across public equities and private placements.
- June 2026 OliX and March 2026 ROKIT show conviction in complex, non-consensus deals.
- Its Brookdale vehicles let Weiss buy structured, illiquid stakes without forced-markdown panic.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Professional Development Budget
Company News
Ionic Digital, a digital infrastructure company supporting AI and high-performance computing, has raised $400 million in an equity private placement, implying a pre-money valuation of $2.0 billion. The round was led by Attestor, Oaktree Capital Management and Sachem Head Capital Management, with participation from Citadel and Weiss Asset Management. The Washington-based company will use the proceeds for general corporate purposes, including developing its digital infrastructure assets. Ionic Digital provides high-performance computing and data centre infrastructure designed for intensive AI workloads. J.P. Morgan and BTIG served as co-placement agents for the transaction, whilst White & Case provided legal counsel to the company.
OliX Pharmaceuticals secures KRW 110 billion investment from BOLD, L'Oréal corporate venture capital fund, and Weiss, U.S. Hedge fund. * Participation of both strategic partner and key global investor * Underlines the potential of OliX Pharmaceuticals' siRNA platform SEOUL, South Korea-(BUSINESS WIRE)-OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that it has raised approximately KRW 110 billion through a third-party allotment of newly issued common shares to strategic investors. The investment was jointly made by BOLD, L'Oréal's corporate venture capital fund, and Weiss Asset Management LP, a U.S. asset management firm. This strategic collaboration combines OliX's world-class siRNA platform capabilities with L'Oréal's century-long commitment to beauty innovation and expertise across biology, tech, and formulation. Share BOLD is L'Oréal's venture investment arm that backs promising beauty brands, biotech, and tech companies, especially those with disruptive innovation potential. The U.S. asset manager is also a key global investor in OliX and participated in this round following its investment in August 2025. With the newly secured funds, the company intends to advance its ongoing siRNA-based projects in several therapeutic areas, including skin- and hair-related projects. The company also expects the investment to further strengthen its strategic partnership with L'Oréal. Through this, the company aims to reinforce its research foundation and accelerate development progress. Guive Balooch, Global Managing Director of Open Innovation and Augmented Beauty at L'Oréal, said, "We are excited to strengthen our scientific partnership with OliX with an equity investment by BOLD. This strategic collaboration combines OliX's world-class siRNA platform capabilities with L'Oréal's century-long commitment to beauty innovation and expertise across biology, tech, and formulation. We are convinced that together we'll accelerate in creating the future of beauty for the benefit of consumers globally with new levels of performance backed by advanced biology and robust scientific proof." Dong Ki Lee, CEO of OliX Pharmaceuticals, said, "We are delighted to secure funding from BOLD and Weiss." He added, "Their support reflects strong confidence in our partnership and shared vision for innovation. The joint participation of a global strategic partner and a major investor reflects strong market confidence in the company's technological competitiveness and future growth potential." About OliX Pharmaceuticals OliX is a biotechnology company focused on the development of innovative therapeutics that regulate disease-causing gene expression based on RNA interference (RNAi) technology. Leveraging RNAi technology, OliX is researching and developing therapeutics for a broad range of diseases, with multiple pipeline programs currently in clinical stages. OliX is developing therapeutics based on its proprietary core drug development platform, OASIS (OliX Advanced Small Interfering RNA System), which is designed to enhance the high gene-silencing efficiency of RNAi technology and enable tissue-specific delivery. Based on this platform, OliX is advancing locally administered RNAi therapeutics for various indications, including hair loss, age-related macular degeneration (AMD), and hypertrophic scars. In addition, by incorporating hepatocyte-specific delivery technology, OliX is building pipelines in liver-related diseases, including metabolic dysfunction-associated steatohepatitis (MASH), obesity, and cardiometabolic disorders. In accordance with its mid- to long-term growth strategy, the "OliX 2.0 Roadmap," OliX continues to expand the application of RNAi therapeutics. The company is building novel delivery platform technologies targeting the central nervous system (CNS) and adipose tissue, expanding its follow-on pipelines, and pursuing differentiated RNAi therapeutics across a broad range of disease areas. Contacts. OliX Pharmaceuticals, Inc. Jiyoun Kim OliX Pharmaceuticals Communications +82-31-779-8407 [email protected] More News From OliX Pharmaceuticals, Inc. SEONGNAM, South Korea-( BUSINESS WIRE )-OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX's OLX75016... SUWON, South Korea-( BUSINESS WIRE )-OliX Pharmaceuticals initiated patient dosing in the Phase 1 clinical trial of OLX75016 for MASH... SUWON, South Korea-( BUSINESS WIRE )-OliX Pharmaceuticals, Inc. received approval from the HREC to conduct a Phase 1 clinical trial of drug candidate OLX75016...
South Korean precision micro-bit manufacturer Neotis has secured 18 billion won ($12.7 million) in strategic investment from Boston-based hedge fund Weiss Asset Management to build a new factory targeting AI semiconductor demand. The facility, scheduled to begin operations in late 2027, will expand the company's micro-bit production capacity. The investment was structured as convertible preferred shares rather than convertible bonds to minimise shareholder dilution, with 662,000 shares issued at 27,199 won each. The shares will be locked up for one year following issuance. Neotis also announced plans to cancel 140,000 treasury shares worth approximately 3.9 billion won. Founded in 2000, Neotis produces ultra-precise drill bits for printed circuit boards used in AI accelerators and semiconductor packaging, holding the leading market share in South Korea.
Rokit Healthcare has raised 62.5 billion won (approximately $45 million) in a Series funding round, with foreign capital accounting for 72% of the total investment. Leading investors include Weiss Asset Management (30 billion won), Oasis Management (7 billion won), Pacific Alliance Group (5 billion won), and LMR (3 billion won). Domestic investors, including NH Investment & Securities, Asem, Anda, GVA, and Milestone Asset Management, contributed 17.5 billion won. The investment, structured as redeemable convertible preferred shares with a one-year lock-up period, aims to minimise short-term share price volatility. The South Korean biotech and regenerative medicine company said the funding marks a turning point in its journey towards becoming a global leader in the sector.
Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today ...